Mathew Wainwright
Director, European Transactions
Mathew Wainwright
mathew@ascensionadvisory.com
+34 635 159 611
Mathew is Director of European Transactions at Ascension. Mathew is responsible for leading European activity with private equity clients and business owners across Europe.
Upon graduating as an Electrical & Electronics Engineer with Management & Entrepreneurship from City, University of London, Mathew started his career in a boutique management consulting firm advising leading industrial clients across Spain.
He then quickly transitioned into private equity investing at Opulentia Capital, a leading private equity firm renowned for its pioneering Buy Build Sell™ strategy, performing buy and build strategies across Europe. During his tenure, he transformed the operations at Opulentia, built out a European expansion team, created technological efficiencies across the company functions, acquired 15 businesses, and built the portfolio turnover to 125 million within 24 months.
His passion for working with business owners and navigating creative deal structures led him to become increasingly passionate about the Sale & Leaseback strategy, and structuring M&A transactions.
In his spare time, you will find him travelling, doing cross-fit, running, playing pádel/badminton/golf, reading, or hanging out with family & friends.
Favorite Quote: If you can get 1 percent better each day for one year, you'll end up thirty-seven times better by the time you're done. Conversely, if you get 1 percent worse each day for one year, you'll decline nearly down to zero.
European SLB Outlook: Country-Level Opportunities in a Stabilizing Macro Environment
As 2026 unfolds, European sale leaseback (SLB) markets are entering a more constructive phase after...
$17.7M Sale Leaseback for an OpenGate Capital Portfolio Company
Ascension Advisory advised OpenGate Capital on the $17.7 million sale leaseback of a 152,256 square...
$28M Pharmaceutical Facility Sale Leaseback for Olympus Partners
Ascension Advisory advised Olympus Partners on a $28 million sale leaseback of a pharmaceutical...